NCT01371565View on ClinicalTrials.gov

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

September 30, 2012

Conditions
Cushing's DiseaseCushing's Syndrome
Interventions
DRUG

Mifepristone

mifepristone at doses from 300mg/day up to 1200mg/day

Trial Locations (5)

21215

Sinai Hospital of Baltimore, Baltimore

33021

The Center for Diabetes and Endocrine Care, Hollywood

43210

The Ohio State University, Division of Endocrinology Diabetes and Metabolism, Columbus

44195

Cleveland Clinic Foundation, Cleveland

48109

University of Michigan Medical Center, Ann Arbor

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY